Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

Mamoru Shibata,1 Tomomi Nakamura,2 Akichika Ozeki,2 Kaname Ueda,2 Russell M Nichols3 1Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; 2Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan; 3Global Medical Affairs, Eli Lilly...

Full description

Bibliographic Details
Main Authors:	Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-12-01
Series:	Journal of Pain Research
Subjects:	mesh: preventive therapy quality of life
Online Access:	https://www.dovepress.com/migraine-specific-quality-of-life-questionnaire-msq-version-21-score-i-peer-reviewed-article-JPR

Similar Items

Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial
by: Fumihiko Sakai, et al.
Published: (2020-07-01)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
by: Michael Ament, et al.
Published: (2021-02-01)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
by: Michael Ament, et al.
Published: (2021-08-01)

The Psychometric Properties of the Persian Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraines
by: Alireza Zandifar, et al.
Published: (2013-01-01)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
by: Stephen D. Silberstein, et al.
Published: (2019-06-01)

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
by: Stephen D. Silberstein, et al.
Published: (2019-12-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
by: Bianca Raffaelli, et al.
Published: (2019-06-01)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-03-01)

Migraine-Specific Quality of Life Questionnaire Chinese version 2.1 (MSQv2.1-C): psychometric evaluation in patients with migraine
by: Hao-Yuan Chang, et al.
Published: (2019-06-01)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
by: Panagiotis Gklinos, et al.
Published: (2020-04-01)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
by: Ammendola, E., et al.
Published: (2022)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
by: Fabrizio Vernieri, et al.
Published: (2021-05-01)

Effect of Moderate Intensity Aerobic Exercise on Migraine Headache Indexes and Quality of Life Improvement in Women with Migraine
by: Z. Pairo, et al.
Published: (2016-09-01)

The validation of the Hungarian version of the ID-migraine questionnaire
by: Éva Csépány, et al.
Published: (2018-11-01)

Validation of the Spanish version of the migraine disability assessment questionnaire (MIDAS) in university students with migraine
by: Daniel Rodríguez-Almagro, et al.
Published: (2020-02-01)

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials
by: Jakub Jedynak, et al.
Published: (2021-05-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
by: Dulanji K. Kuruppu, et al.
Published: (2021-04-01)

ID-Migraine™ questionnaire and accurate diagnosis of migraine
by: Ana Carolina Musser Tavares de Mattos, et al.

CORRELATION BETWEEN MIGRAINE SEVERITY AND COMORBIDITIES IN EPISODIC MIGRAINE PATIENTS
by: Adriana Bulboaca, et al.
Published: (2015-06-01)

Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
by: Lupi C, et al.
Published: (2019-04-01)

Episodic Mydriasis as Migraine Equivalent
by: J Gordon Millichap
Published: (1991-10-01)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
by: Pellesi L, et al.
Published: (2020-07-01)

Efficacy and safety of erenumab in the preventive treatment of migraine in adults: a systematic review
by: Yan LIN, et al.
Published: (2018-09-01)

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
by: Kaname Ueda, et al.
Published: (2019-06-01)

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
by: Stefanie Förderreuther, et al.
Published: (2018-12-01)

Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome
by: Rebecca M. Speck, et al.
Published: (2019-07-01)

The Integration of Aluminum and MSQ
by: Hao Hsu, et al.
Published: (2000)

CURRENT THERAPIES IN EPISODIC MIGRAINE MANAGEMENT
by: Adina Roceanu,, et al.
Published: (2014-12-01)

Migraine Episodes Following Cranial Irradiation
by: J Gordon Millichap
Published: (1995-11-01)

The acute and preventative treatment of episodic migraine
by: Sarah Miller
Published: (2012-01-01)

Migraine with benign episodic unilateral mydriasis
by: Jabr FI, et al.
Published: (2011-06-01)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
by: Yanbo Yang, et al.
Published: (2020-02-01)

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
by: Jessica Ailani, et al.
Published: (2020-10-01)

Validity, Reliability and Application of the Taiwan Version of the Migraine Disability Assessment Questionnaire
by: Pei-Hua Hung, et al.
Published: (2006-01-01)

Validity and Reliability of the Bahasa Melayu Version of the Migraine Disability Assessment Questionnaire
by: Munvar Miya Shaik, et al.
Published: (2014-01-01)

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
by: Virginia L. Stauffer, et al.
Published: (2020-05-01)

Cannot write session to /tmp/vufind_sessions/sess_gsc0t1v1c74b43mmbbgmnhh8mo